Evidence map›Paper›PMID 26540407›Full record

ArticleAging2015

The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells.

Sarah Waye, Aisha Naeem, Muhammad Umer Choudhry, Erika Parasido, Lucas Tricoli, Angiela Sivakumar, John P Mikhaiel, Venkata Yenugonda, Olga C Rodriguez, Sana D Karam and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. MDM2- an indispensable player in tumorigenesis.Molecular biology reports · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Zinc and zinc-containing biomolecules in childhood brain tumors.Journal of molecular medicine (Berlin, Germany) · 2016
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Sarah WayeLombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
Aisha NaeemLombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
Muhammad Umer ChoudhryLombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
Erika ParasidoLombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
Lucas TricoliLombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
Angiela SivakumarLombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
John P MikhaielLombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
Venkata YenugondaLombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
Olga C RodriguezLombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
Sana D KaramDepartment of Radiation Oncology, University of Colorado, Denver, CO 80208, USA.
Brian R RoodCenter for Cancer and Immunology Research, Children's National Medical Center, Washington, DC 20057, USA.
Maria Laura AvantaggiatiLombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
Chris AlbaneseLombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.
Georgetown University Medical Center · USGeorgetown University · USChildren's National · USUniversity of Colorado Denver · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
TRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8M
Role of the mitochondrial citrate carrier SLC25A1(CIC)in cancer progression and therapyR01CA193698 · NCI · GEORGETOWN UNIVERSITY · PI AVANTAGGIATI, MARIA L · 2015 to 2019
$1.8M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA051008NCI NIH HHS P30 CA51008-18NCI NIH HHS R01 CA193698NCI NIH HHS R01CA193698NCI NIH HHS T32 CA009686
6 · The paper itself

Abstract

Medulloblastoma (MB), a primitive neuroectodermal tumor, is the most common malignant childhood brain tumor and remains incurable in about a third of patients. Currently, survivors carry a significant burden of late treatment effects. The p53 tumor suppressor protein plays a crucial role in influencing cell survival in response to cellular stress and while the p53 pathway is considered a key determinant of anti-tumor responses in many tumors, its role in cell survival in MB is much less well defined. Herein, we report that the experimental drug VMY-1-103 acts through induction of a partial DNA damage-like response as well induction of non-survival autophagy. Surprisingly, the genetic or chemical silencing of p53 significantly enhanced the cytotoxic effects of both VMY and the DNA damaging drug, doxorubicin. The inhibition of p53 in the presence of VMY revealed increased late stage apoptosis, increased DNA fragmentation and increased expression of genes involved in apoptosis, including CAPN12 and TRPM8, p63, p73, BIK, EndoG, CIDEB, P27Kip1 and P21cip1. These data provide the groundwork for additional studies on VMY as a therapeutic drug and support further investigations into the intriguing possibility that targeting p53 function may be an effective means of enhancing clinical outcomes in MB.

Indexed as

AdenineAntineoplastic AgentsCell DeathCell Line, TumorDansyl CompoundsDrug Evaluation, PreclinicalHumansMedulloblastomaSignal TransductionTumor Suppressor Protein p532-chloro-N-(2-(5-(dimethylamino)naphthalene-1-sulfonamido)ethyl)-4-(2-(1-hydroxy-3-methylbutan-2-ylamino)-9-isopropyl-9H-purin-6-ylamino)benzamideAdenineAntineoplastic AgentsDansyl CompoundsTumor Suppressor Protein p53apoptosisautophagyBIKEndonuclease Gmedulloblastomap53p63p73

Identifiers

PMID26540407
PMCPMC4637210
OpenAlexW2169933219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.